Michelle Gilliatte, MD
Family Medicine · Indianapolis, INNPI 1184078909
Payments from drug & device makers
Across 145 payments — averaging $18.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$514
- Bayer$350
- Dexcom, Inc.$330
- AstraZeneca$175
- Pfizer$150
- Exact Sciences$130
- plus $1K from 18 others
What the payments were for
- Food & beverage$2,64799%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 27 | $514 |
| Bayer | 21 | $350 |
| Dexcom, Inc. | 17 | $330 |
| AstraZeneca | 11 | $175 |
| Pfizer | 9 | $150 |
| Exact Sciences | 7 | $130 |
| Medtronic | 1 | $115 |
| Idorsia Pharmaceuticals US Inc | 5 | $96 |
| E.r. Squibb & Sons, L.L.C. | 6 | $92 |
| Novo Nordisk | 5 | $91 |
| Abbott | 4 | $85 |
| Axsome Therapeutics, Inc. | 4 | $85 |
| Boehringer Ingelheim | 4 | $73 |
| GSK | 4 | $63 |
| Otsuka America Pharmaceutical, Inc. | 3 | $56 |
| Amgen | 3 | $51 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $49 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $45 |
| Lilly USA, LLC | 3 | $43 |
| Merz North America, Inc. | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Novartis | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$115
How this compares
$2,667 in reported general payments places this provider in the 75th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 86 | $137,016 |
| MounjaroTirzepatide | 80 | $109,957 |
| JardianceEmpagliflozin | 51 | $61,354 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $35,902 |
| TrulicityDulaglutide | 18 | $27,630 |
| EliquisApixaban | 22 | $27,134 |
| XareltoRivaroxaban | 17 | $26,046 |
| JanuviaSitagliptin Phosphate | 21 | $24,314 |
| RexultiBrexpiprazole | 11 | $17,209 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $13,524 |
| LinzessLinaclotide | 15 | $11,671 |
| Emgality PenGalcanezumab-Gnlm | 14 | $9,729 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $8,942 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 40 | $8,917 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 67 | $7,923 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $43 | $137,58798 claims |
| Novo NordiskOzempic | $91 | $137,01686 claims |
| Boehringer IngelheimJardiance | $73 | $61,35451 claims |
| GSKTrelegy Ellipta, Shingrix | $63 | $44,81981 claims |
| PfizerEliquis, Abrysvo | $150 | $31,25035 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $56 | $17,20911 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $175 | $13,28629 claims |
| AbbVieLinzess | $514 | $11,67115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Indianapolis
- Blair BrengleIndianapolis$10.6M
- Steven SmithIndianapolis$2.5M
- Richard TannerIndianapolis$1.6M
- Richard FeldmanIndianapolis$476K
- Joe BanksIndianapolis$294K
- Jakoda SniderIndianapolis$107K
- Robert ClutterIndianapolis$77K
- Gaylen KeltonIndianapolis$42K
- Daniela LoboIndianapolis$38K
- Haihong MaoIndianapolis$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.